Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PHARMACIA NICOTINE NASAL SPRAY DISTRIBUTION RECORDS

This article was originally published in The Tan Sheet

Executive Summary

PHARMACIA NICOTINE NASAL SPRAY DISTRIBUTION RECORDS should be required to help prevent abuse of the smoking cessation product if it is approved for marketing, FDA's Drag Abuse Advisory Committee recommended Aug. 1. The committee also recommended that a limit be imposed on the number of refill prescriptions patients could obtain without reassessment by the prescriber. The panel recommended against requiting triplicate prescriptions or secured storage areas for the product. Pharmacia's NDA for the nicotine nasal spray as a prescription aid to smoking cessation was filed in July 1993.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS083099

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel